Le Lézard
Classified in: Health
Subject: PDT

Alma, a Sisram Medical Company, Launches Alma Hybridtm, the First and Only Device of Its Kind - Exclusively Combining Three Powerful Energy Sources to Deliver Unparalleled Results


NUREMBERG, Germany, Oct. 22, 2020 /PRNewswire/ -- Alma, one of the top five global leaders of energy-based medical and aesthetics solutions, unveiled its new Alma Hybridtm platform today, during a worldwide LIVE launch event, which was broadcasted from a state-of-the-art studio that was built especially at Alma's headquarters for this event.

Designed to enable endless options of ablative, non-ablative and thermal treatments for skin rejuvenation and scar revision, Alma Hybridtm creates a unique synergistic effect by combining the power of three core energies, including:

At the heart of the Alma Hybridtm platform is HyGridtm, Alma's novel hybrid applicator, which facilitates a customized skin-program matrix for any desired combination of ablation vs. non ablation ratio within the treated area. HyGridtm enables practitioners to meet each and every patient's specific treatment needs, as well as the desired balance between results timeline and patient's downtime.

In addition to this powerful combination of tools, Alma Hybridtm smart software serves as a key solution component, which enables practitioners to craft "signature treatments" that bring their unique skills and experience into action.

"The revolutionary HyGridtm mode allows me to customize the optimal ratio between CO[2] and non-ablative treatments and to maximize the effect of each laser wavelength. I find this to be a substantial step forward in terms of the personalization of laser treatments for various skin conditions," said Dr. Ofir Artzi, Chairman of SCARS, the international scar treatment conference.

"We are extremely proud to deliver the magic 'behind the scenes' that enables top practitioners to bring their skills and experience to light," said Lior Dayan, CEO of Alma. "This is a milestone for us as a company, as well as for all medical professionals who will be using it, and for the patients who will enjoy its remarkable results."

About Alma

Alma is a global innovator of Laser, Light-based, Radiofrequency, Plasma and Ultrasound solutions for the aesthetic and surgical markets. We enable practitioners to offer safe and effective procedures while allowing patients to benefit from state-of-the-art, clinically proven technologies and treatments. https://www.almalasers.com

Video -  https://youtu.be/cjSb3_BvZOg


These press releases may also interest you

at 01:00
PARIS, FRANCE, 24 April 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2024. ? ?  Q1 2024? Q1 2023? % change? ?m? ?m? ActualCER1Growth...

23 avr 2024
GenScript, a global leader in life sciences and biotechnology, successfully hosted an Open Day event at its Singapore facility on the 16th of April, welcoming more than 50 representatives from Singapore. This event provided an exclusive look into...

23 avr 2024
Cybervation, an award-winning global technology and healthcare solutions company, proudly announces that its CEO, Purba Majumder, has been distinguished as one of the 2024 100 Women to KNOW Across America. This award from KNOW Women recognizes...

23 avr 2024
The report titled "Glycated Albumin Assay Market by Product (Animal Glycated Albumin Assay, Human Glycated Albumin Assay), Application (Prediabetes, Type 1 Diabetes, Type 2 Diabetes), End User - Global Forecast 2024-2030" is now available on...

23 avr 2024
The report titled "Health & Wellness Food Market by Type (Fresh & Natural, Functional Foods & Beverages, Heat & Eat), Nature (Genetically Modified Organism Food, Non-Genetically Modified Organism Food), Fat Content, Category, Free From Category,...

23 avr 2024
Hanmi Pharmaceutical (KOSPI: 128940, CEO: Jae-Hyun Park), a leading biopharma company in Korea that focuses on research areas such as oncology, obesity/metabolism, and rare diseases, announced it has entered into a Clinical Trial Collaboration and...



News published on and distributed by: